Updates are available Correction dated 2023-02-20
Click to view Correction: https://0-doi-org.brum.beds.ac.uk/10.1186/s13045-023-01414-8
Updates are available Correction dated 2022-10-31
Click to view Correction: https://0-doi-org.brum.beds.ac.uk/10.1186/s13045-022-01369-2
-
Authors
Jiang, Qian
Li, Zongru
Qin, Yazhen
Li, Weiming
Xu, Na
Liu, Bingcheng
Zhang, Yanli
Meng, Li
Zhu, Huanling
Du, Xin
Chen, Suning
Liang, Yang
Hu, Yu
Liu, Xiaoli
Song, Yongping
Men, Lichuang
Chen, Zi
Niu, Qian
Wang, Hengbang
Lu, Ming
Yang, Dajun
Zhai, Yifan
Huang, Xiaojun
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03883087 at ClinicalTrials.govnct03883100 at ClinicalTrials.govDocuments that mention this clinical trial
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
https://0-doi-org.brum.beds.ac.uk/10.1186/s13045-022-01334-z
Documents that mention this clinical trial
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
https://0-doi-org.brum.beds.ac.uk/10.1186/s13045-022-01334-z
-
Funding
Funding for this research was provided by:
National Nature Science Foundation of China (No. 81770161, No. 81970140)
National Science and Technology Major Project (No. 2018ZX09301021-005)
Ascentage Pharma Group Corp Ltd
National Key Research and Development Program of China (No. 2017YFA0104500)
Foundation for Innovative Research Groups of the National Natural Science Foundation of China (No. 81621001)
Key Program of the National Natural Science Foundation of China (No. 81530046, 81930004)
- License Information
-
More Information
Article History
Received: 29 April 2022
Accepted: 4 August 2022
First Online: 18 August 2022
Change Date: 31 October 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://0-doi-org.brum.beds.ac.uk/10.1186/s13045-022-01369-2
Change Date: 20 February 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://0-doi-org.brum.beds.ac.uk/10.1186/s13045-023-01414-8
Declarations
:
: Studies were conducted in compliance with the Declaration of Helsinki, with protocols approved by institutional review boards. Written informed consent was obtained from all patients prior to the initiation of any study-specific procedures.
: All authors confirmed and had consent to publish the manuscript on Journal of Hematology & Oncology.
: ZC, QN, SZ, LM, ML, HW, CY, DY, and YZ: Employees of, and shareholders in, Ascentage Pharma. DY and YZ: Hold positions of leadership within Ascentage. All other authors declare no competing interests.
